Please enable JS

Investors & Media

OVERVIEW

CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. Our multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Our lead program, CTX001, aims to treat Sickle cell disease and ß-thalassemia using an ex vivo approach. We are also pursuing oncology indications with our allogeneic CAR-T platform and liver, lung, and neuromuscular indications using in vivo approaches. In addition, we have established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases with high unmet need. We have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from our scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. We are headquartered in Zug, Switzerland with R&D operations in Cambridge, Massachusetts, USA and select business operations in London, United Kingdom.

 

For more information on the foundational CRISPR/Cas9 patent estate, please visit the CRISPR Collective website here.




Corporate Presentation

Preview of Module presentationsArchiveAudioColumn01.3
CRISPR Therapeutics Corporate Presentation

Recent News

CRISPR Therapeutics Announces Presentations at the ASGCT 21st Annual Meeting
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2018 Financial Results
CRISPR Therapeutics to Participate in May Investor Conferences

View More


Upcoming Events & Recent Presentations

There are currently no events scheduled.
DateTitle
5/15/18
 2018 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting Poster: Allogeneic CAR-T Cells with Multiple Therapeutically Favorable Edits Can Be Created Efficiently Using CRISPR/Cas9
4/16/18
 2018 American Association for Cancer Research (AACR) Annual Meeting Poster: Allogeneic Chimeric Antigen Receptor T Cells Targeting B Cell Maturation Antigen
4/16/18
 2018 American Association for Cancer Research (AACR) Annual Meeting Poster: Allogeneic CRISPR Engineered Anti-CD70 CAR-T Cells Demonstrate Potent Preclinical Activity Against Both Solid and Hematological Cancer Cells
12/10/17
 2017 American Society of Hematology Annual Meeting Presentation: CRISPR/Cas9 Genome Editing to Treat Sickle Cell Disease and ß-Thalassemia: Re-Creating Genetic Variants to Upregulate Fetal Hemoglobin Appear Well-Tolerated, Effective and Durable
11/10/17
 SITC 2017 Investor Reception Presentation
11/10/17
 Production of Site-specific Allogeneic CAR-T Cells by CRISPR/Cas9 for B-Cell Malignancies
6/23/17
 2017 European Hematology Association Annual Congress Presentation
5/23/17
 UBS Global Healthcare Conference Presentation
5/03/17
 42nd Annual Deutsche Bank Health Care Conference Presentation
4/06/17
 2017 Needham Conference Presentation
12/06/16
 Re-Creating Hereditary Persistence of Fetal Hemoglobin (HPFH) to treat Sickle Cell Disease and ß-thalassemia poster presented at the 2016 American Society of Hematology Annual Meeting
12/06/16
 CRISPR/Cas9-mediated genome editing of Human CD34+ cells upregulate fetal hemoglobin to clinically relevant levels in single cell-derived erythroid colonies poster presented at the 2016 American Society of Hematology Annual Meeting

View More




Print Page E-mail Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet